ARPA-H Health Science Futures (HSF) Mission Office BAA
Executive Summary:
The ARPA-H Health Science Futures (HSF) Mission Office is accepting Solution Summaries and full proposals for revolutionary health R&D under its Innovative Solutions Opening (ISO), ARPA-H-SOL-24-104. Multiple awards are anticipated via Other Transaction (OT) agreements. The ISO remains open through March 5, 2029, and you must submit a short Solution Summary and receive written feedback before a full proposal. Submissions must align with HSF focus areas (e.g., breakthrough technologies, transformative tools, and adaptable platform systems) and are expected to be high-risk, high-impact—incremental or clinical-trial-stage efforts are out of scope.
How much funding would I receive?
The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.
What could I use the funding for?
This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. The HSF mission office expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. The HSF mission office
supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change. Specifically excluded from consideration are proposals that represent an evolutionary or incremental advance in the current state of the art, or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed toward policy changes; traditional education and training; center coordination, formation, or development; and construction of physical infrastructure are outside the scope of the ARPA-H mission.
The following areas define the ground-breaking research that HSF seeks to support:
-
Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions.
Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods.
Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need.
Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems.
Novel approaches to definitively diagnose and cure chronic diseases including, but not limited to, diabetes, autoimmune diseases, neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, ALS, etc.), and cancer.
Technologies that expand the precision, scale, and accessibility of brain circuit mapping technologies that enable causative neuropsychiatric links to mental health disorders leading to definitive diagnosis and reliable therapeutic monitoring.
-
Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care.
Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease.
Development of bionic or biohybrid devices that enable direct integration and communication with the body to activate restorative pathways that restore lost senses, physical abilities, immune functions, and other organ functions.
Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders.
Synthetic biology approaches incorporating novel logic mechanisms, disease targeting and response methods, and robust control strategies to diagnose, and/or cure a multitude of diseases.
Imaging or other technologies engineered from discoveries at the forefront of physics and/or chemistry that reduce cost, improve size and/or portability, increase availability, expand capability, improve resolution, reduce exposure to radiation, and accommodate pediatric patient populations.
Integrated sensing and therapy delivery devices for addressing chronic health conditions, including mental health conditions or substance use disorders.
-
Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs.
Novel molecular platforms to target and cure diseases, including the modulation of physiological systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes.
New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed.
Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.
Revolutionary omics platforms that enable unprecedented spatial and temporal scales and resolution of physiological and disease mechanisms.
-
Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the other listed topics.
Proposals in response to this Innovative Solutions Opening (ISO) are expected to identify innovative approaches to enable revolutionary advances in medicine and healthcare and the science and technologies underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that offer radically new insights to address specific health conditions, including (but not limited to) cancer, cardiovascular, diabetes, infectious and neurological diseases, and pediatric and maternal/fetal health.
Are there any additional benefits I would receive?
Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Health Science Futures (HSF) agreement:
Government Validation and Credibility:
Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.Enhanced Market Visibility and Notoriety:
Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.Ecosystem Access and Collaboration Opportunities:
ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.Nondilutive Growth and Strategic Leverage:
Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.
What is the timeline to apply and when would I receive funding?
Open period: now through March 5, 2029.
Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.
Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).
Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.
Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.
Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.
Where does this funding come from?
The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.
Who is eligible to apply?
Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.
What companies and projects are likely to win?
Reviewers assess (in descending importance):
Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;
Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);
Team capabilities/experience—track record delivering similar efforts on budget/schedule;
Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.
Are there any restrictions I should know about?
Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.
Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.
How much would BW&CO Charge?
Our full service support is available for a flat fee of $4,000 to submit a solution summary.
Fractional support is $300 per hour.
For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.